1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

Not Too ATTRACTive Data For Catheter Thrombolysis In Combatting Post-Thrombotic Syndrome

 
• By Reed Miller

Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.

blood clot
• Source: shutterstock.com

Two-year results of the ATTRACT trial show that pharmacomechanical catheter-directed thrombolysis (PCDT) to treat deep-vein thrombosis does not reduce the patients’ chances of developing post-thrombotic syndrome, but does increase their risk of major bleeding compared anticoagulation drug therapy alone.

“[ATTRACT] provides the first high quality data on PCDT and will enable doctors to target its use to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

Medtronic Posts Solid First-Quarter, Adds Board Members As Elliott Takes Stake

 
• By Marion Webb

Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.

Even ‘Small’ Leaks After Left Atrial Appendage Occlusion Raises Stroke Risk, Study Finds

 
• By Brian Bossetta

A Japanese study of Watchman LAA closure devices found that leaks of any size after implantation raise the risk of stroke. The study comes shortly after the US FDA issued an early alert for the Watchman access systems.

Philips Announces Major Investment In US Manufacturing And Expansion Of Pennsylvania Facility

 
• By Brian Bossetta

Philips says the expansion of its facility in Reedsville, PA, will not only boost its capacity to produce AI-enabled ultrasounds that are used in hospitals across the US but will also create 120 well-paying jobs.

Injuries And Deaths Linked To Boston Scientific Cardiac Devices. Company Responds

 
• By Brian Bossetta

The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.

More from Device Area

Why EU Innovators Face Growing Barriers With EU Combination Product Regulation

 
• By Amanda Maxwell

Combination products are no longer fringe – they are the “new normal,” consultant Stephen O’Rourke told Medtech Insight. The EU has the expertise to handle the regulatory complexity, but only if connects the dots between silos. That’s the challenge, he said, and the opportunity.

NeuroOne Prepares To Launch Trigeminal Nerve Ablation System

 
• By Elizabeth Orr

The US FDA has cleared NeuroOne's OneRF trigeminal nerve ablation system for the treatment of trigeminal neuralgia. This minimally invasive method utilizes radio frequency energy to alleviate pain, offering an alternative to traditional medications and surgeries. A fall commercial launch is planned.

Industry Experts Expect AI-Driven Medtech M&A To Continue In 2025

 
• By Marion Webb

AI-driven medtech M&A slowed slightly in volume but tripled in value in early 2025, with buyers focusing on AI-driven diagnostics, surgical tech and analytics. Industry experts expect continued high-value deals as firms defend market share and pursue workflow-enhancing AI.